Two trials comparing transcatheter (TAVR) with surgical aortic valve replacement in patients at low surgical risk found TAVR to yield equal or better outcomes. While a new indication seems certain, some key questions remain.
A new analysis of the large TVT Registry provides the strongest evidence to date of a prognostic benefit from renin-angiotensin system inhibitor therapy following transcatheter aortic valve replacement.
The next waves of progress in transcatheter aortic valve replacement are likely to involve expanding indications, valve refinements and new accessory treatments.
Our experts outline their vision of ideal changes to the National Coverage Determination for programs performing transcatheter aortic valve replacement. A CMS decision is due in June 2019.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The latest PARTNER 2A analysis finds that worsening RV function is much more common after SAVR than TAVR. And it predicts greater risk for poor outcomes regardless of procedure type.
In this Q&A, Cleveland Clinic experts explore how to weigh patient age when deciding between surgical and transcathether AVR and what matters most to procedure choice for treating a degenerated aortic bioprosthesis.
The lead investigator of the pivotal SENTINEL trial explains what the data suggest about when to use the newly FDA-approved Sentinel device for cerebral embolic protection during TAVR procedures.
The pivotal SENTINEL trial’s lead investigator weighs in on the FDA’s approval of the first device for cerebral embolic protection during transcatheter aortic valve replacement procedures.
A Cleveland Clinic interventional cardiologist puts the SURTAVI trial in context and speaks to what’s needed to help intermediate-risk patients make the best choice between two good AVR options.
The lead investigator of the STS/ACC TVT Registry study presented at ACC.17 explains why its findings suggest valve-in-valve TAVR might be the treatment of choice for inoperable and even high-risk patients.